Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Barnett RM, Jang A, Lanka S, Fu P, Bucheit LA, Babiker H, Bryce A, Meyer HM, Choi Y, Moore C, Garje R, Gao X, Kim DW, Chang RY, Gulhati P, Ramaker R, Bansal R, Zhang T, Oliver Sartor A, Armstrong AJ, Bilen MA, Barata P.
Barnett RM, et al. Among authors: chang ry.
Commun Med (Lond). 2024 Dec 2;4(1):256. doi: 10.1038/s43856-024-00687-5.
Commun Med (Lond). 2024.
PMID: 39623081
Free PMC article.